BL M05D1
Alternative Names: BL-M05D1Latest Information Update: 31 Jul 2025
At a glance
- Originator Sichuan Baili Pharmaceutical; SystImmune
- Developer Sichuan Baili Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Jun 2025 SystImmune plans to initiate a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) (IV) (NCT07021066)
- 19 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06349811)
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in solid tumor were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)